Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Assessment of safety reports on adverse events of biologics and biosimilars reported to the FDA Adverse Event Reporting System (FAERS)

Next Previous
X
Search
Trial Profile

Assessment of safety reports on adverse events of biologics and biosimilars reported to the FDA Adverse Event Reporting System (FAERS)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Jun 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alemtuzumab (Primary) ; Atezolizumab (Primary) ; Bevacizumab (Primary) ; Interferon alpha-2a (Primary) ; Interferon beta-1a (Primary) ; Interferon beta-1b (Primary)
  • Indications Cancer
  • Focus Adverse reactions

    • Most Recent Events

    • 02 Jun 2021 New trial record
    • 20 May 2021 Results presented at the 26th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top